Suppr超能文献

抗抑郁药的药理学特性。

The pharmacological properties of antidepressants.

机构信息

Center of Neuropharmacology, Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Italy.

出版信息

Int Clin Psychopharmacol. 2010 May;25(3):117-31. doi: 10.1097/YIC.0b013e3283311acd.

Abstract

Antidepressant drugs represent one of the main forms of effective treatment for the amelioration of depressive symptoms. Most available antidepressants increase extracellular levels of monoamines. However, it is now recognized that monoamine levels and availability are only part of the story, and that antidepressants whose mechanism of action is mainly based on the modulation of monoaminergic systems may not be able to satisfy the unmet needs of depression. Therefore, a number of compounds, developed for their potential antidepressant activity, are endowed with putative mechanisms of action not affecting traditional monoamine targets. This article briefly reviews, within a mechanistic perspective, the pharmacological profiles of representative antidepressants from each class, including monoamine oxidase inhibitors, tricyclics, norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, norepinephrine and serotonin reuptake inhibitors, antidepressants interacting with dopaminergic, melatonergic, glutamatergic, or neuropeptide systems. The undesirable side effects of currently used antidepressants, which can often be a reason for lack of compliance, are also considered.

摘要

抗抑郁药物是改善抑郁症状的主要有效治疗方法之一。大多数可用的抗抑郁药可增加单胺类物质的细胞外水平。然而,现在人们认识到,单胺类物质的水平和可及性只是故事的一部分,而其作用机制主要基于单胺能系统调节的抗抑郁药可能无法满足抑郁症的未满足需求。因此,许多具有潜在抗抑郁活性的化合物具有不影响传统单胺靶点的假定作用机制。本文简要综述了每一类具有代表性的抗抑郁药的药理学特征,包括单胺氧化酶抑制剂、三环类抗抑郁药、去甲肾上腺素再摄取抑制剂、选择性 5-羟色胺再摄取抑制剂、去甲肾上腺素和 5-羟色胺再摄取抑制剂、与多巴胺能、褪黑素能、谷氨酸能或神经肽系统相互作用的抗抑郁药。还考虑了目前使用的抗抑郁药的不良副作用,这些副作用往往是缺乏依从性的原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验